ClinicalTrials.gg
RecruitingNCT07513285Updated Nov 13, 2026

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

A Phase 2 interventional study of Ibezapolstat in Clostridium Difficile Infection Recurrence, sponsored by Acurx Pharmaceuticals Inc.. Recruiting at 19 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Acurx Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 13, 2026Study contact changedSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Clostridium Infections with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Clostridium Infections · United States.

Planned enrollment
71st of 102
20 · median 57
Started
2026
with 5 others
Phase 2
32 of 121
4 open now
Primary completion
2027-09
later than 9 of 18 live
Registered
118th of 121
by date

Among the 121 studies in Clostridium Infections with a site in United States, this one is the 71st largest by planned enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2026, is one of 32 in phase 2, reaches primary completion later than 9 of the 18 other live ones, and was the 118th registered.

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

Browse Clostridium Infections studies →

Open to participants now

16 of the 121 studies in Clostridium Infections with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Clostridium Infections with a site in United States, or all of them as a file.
02

Study summary

Single-arm trial to evaluate the safety and efficacy of ACX-362E [ibezapolstat] in patients with recurrent C. difficile infection (CDI).

Read the detailed description

Phase 2 multicenter, open-label, single-arm study is designed to evaluate the efficacy, safety, and tolerability of ibezapolstat in the treatment and reduction of recurrence of CDI in an adult patient population that has experienced ≥3 episodes of CDI within the past 12 months. Up to 20 participants will be treated with ibezapolstat 450 mg taken with food every 12 hours for 14 days (28 total doses) and followed for Clinical Cure (Day 16), Sustained Clinical Cure (Day 42), rate of CDI recurrence (Up to Week 24), and Extended Clinical Cure (ECC) (Up to Week 24).

03

Conditions studied

  • Clostridium Difficile Infection Recurrence

Keywords

  • Clostridioides difficile
  • Cdiff
  • Recurrent Clostridioides difficile
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before study Day 1, AND 2) a stool test result positive for the presence of C. difficile free toxins
  • Three or more CDI episodes in the past 12 months, including the current episode, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive C. difficile toxin test.
  • At least 1 of the protocol-qualifying prior CDI episodes, not including the current episode, has been treated with oral vancomycin or with fidaxomicin

Exclusion criteria

Exclusion Criteria:

  • Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure \< 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon
  • Received more than 24 hours of dosing with antibiotics for the current CDI episode:
  • Received a live biotherapeutic product (LBP) (Rebyota® or Vowst™) within the past 12 weeks
  • Received or current use of anti-C. difficile antibodies, eg, IV immunoglobulin [IVIG], bezlotoxumab
  • Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) with chronic diarrhea within 12 weeks before Baseline, or with a history of symptoms > 12 weeks before Baseline without evidence of mucosal healing on colonoscopy within the past year.
  • Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks.
  • Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, other bacteria, a parasite, or a virus within the past 2 weeks
  • Major GI surgery (eg, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).
  • Known current history of a severely compromised immune system
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ibezapolstat

    Active investigational antibacterial agent

    Drug: Ibezapolstat

Interventions

  • DrugIbezapolstat

    Ibezapolstat 450 mg po Q12H x14 days

    Also known as: ACX-362E

06

What researchers measure

Primary outcomes

  1. Evaluate the rate of CDI Clinical Cure (CC)

    Time frame: Day 16

  2. Evaluate the rate of Sustained Clinical Cure (SCC)

    Time frame: Day 42

  3. Evaluate the rate of CDI recurrence (rCDI)

    Time frame: Day 70

Secondary outcomes

  1. Assess the rate of CDI recurrence (rCDI)

    Time frame: Day 42

  2. Assess the effects of ibezapolstat on quantitative changes to the fecal microbiome

    The Shannon Diversity Index and Inverse Simpson Diversity Index will be used to quantify biodiversity in a community like the gut microbiome, measuring how many different species are present in a community (richness) and how close in numbers different species in the community are to each other (evenness).

    Time frame: Day 1 to Week 24

  3. Assess time to resolution of diarrhea during the treatment period

    Time frame: Day 16

  4. Assess the incidence of Extended Clinical Cure (ECC)

    Time frame: Weeks 8, 12, and 24

  5. Assess the rate of CDI recurrence (rCDI)

    Time frame: Weeks 12 and 24

Other outcomes

  1. Determine the frequency and severity of adverse events

    Time frame: Day 1 to Week 24

07

Study locations

15 of 19 sites recruiting
  • UC Davis Medical Center
    Sacramento, California 95817, United States
    Not yet recruiting
  • Gastroenterolgy Center of Conneticut
    Hamden, Connecticut 06518, United States
    Recruiting
  • Florida International Medical Research
    Coral Gables, Florida 33134, United States
    Recruiting
  • L&A Morales Healthcare, Inc
    Hialeah, Florida 33012, United States
    Recruiting
  • San Marcus Research Clinc, Inc
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Belis Delgado, MD PA
    Miami Springs, Florida 33166, United States
    Recruiting
  • Infectious Disease Consultants of Georgia
    Athens, Georgia 30606, United States
    Recruiting
  • Snake River Research PLLC
    Idaho Falls, Idaho 83404, United States
    Recruiting
  • Endevour Health
    Skokie, Illinois 60077, United States
    Recruiting
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
    Recruiting
  • University of Massachusetts Memorial Healthcare
    Worcester, Massachusetts 01655, United States
    Recruiting
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Recruiting
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Not yet recruiting
  • DiGiovanna Institute for Medical Education and Research
    Massapequa, New York 11758, United States
    Recruiting
  • Gastroenterology Associates of the Piedmont, PA
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
    Not yet recruiting
  • Romano, Pontzer & Associated
    Pittsburgh, Pennsylvania 15215, United States
    Recruiting
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah 84115, United States
    Not yet recruiting
08

References and documents

Publications

  • Xu WC, Silverman MH, Yu XY, Wright G, Brown N. Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. Bioorg Med Chem. 2019 Aug 1;27(15):3209-3217. doi: 10.1016/j.bmc.2019.06.017. Epub 2019 Jun 11. PubMed 31221610 ↗
  • McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149. PubMed 29562266 ↗
  • Garey KW, McPherson J, Dinh AQ, Hu C, Jo J, Wang W, Lancaster CK, Gonzales-Luna AJ, Loveall C, Begum K, Jahangir Alam M, Silverman MH, Hanson BM. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 Sep 30;75(7):1164-1170. doi: 10.1093/cid/ciac096. PubMed 35134880 ↗
  • Eubank TA, Jo J, Alam MJ, Begum K, McPherson JK, Le TM, Horvath TD, Haidacher SJ, Poggio EC, Lin R, Yue CS, Ducharme MP, Koudssi G, Mercier J, Alder JD, Silverman MH, Garey KW; Ibezapolstat Phase 2 Investigator Group. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025 Aug;6(8):101126. doi: 10.1016/j.lanmic.2025.101126. Epub 2025 Jun 11. PubMed 40516571 ↗

Individual participant data

Plan to share: No

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 23 phase 2 interventional studies under Clostridium Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 12 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 7, 2026
StartActual
Sep 25, 2026was Aug 2026
Primary completionEst.
Sep 29, 2027
CompletionEst.
Nov 24, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. 12 sites changed recruiting status (12 now recruiting)
Show 12 sites
  • Gastroenterolgy Center of Conneticut · Hamden, United StatesNot yet recruiting→Recruiting
  • Florida International Medical Research · Coral Gables, United StatesNot yet recruiting→Recruiting
  • San Marcus Research Clinc, Inc · Miami Lakes, United StatesNot yet recruiting→Recruiting
  • Belis Delgado, MD PA · Miami Springs, United StatesNot yet recruiting→Recruiting
  • Infectious Disease Consultants of Georgia · Athens, United StatesNot yet recruiting→Recruiting
  • DiGiovanna Institute for Medical Education and Research · Massapequa, United StatesNot yet recruiting→Recruiting
  • Romano, Pontzer & Associated · Pittsburgh, United StatesNot yet recruiting→Recruiting
  • Southern Star Research Institute, LLC · San Antonio, United StatesNot yet recruiting→Recruiting
  • Endevour Health · Skokie, United StatesNot yet recruiting→Recruiting
  • Newton-Wellesley Hospital · Newton, United StatesNot yet recruiting→Recruiting
  • University of Massachusetts Memorial Healthcare · Worcester, United StatesNot yet recruiting→Recruiting
  • Henry Ford Hospital · Detroit, United StatesNot yet recruiting→Recruiting
Show 4 added (4 United States)
  • University of Minnesota · Minneapolis, United States
  • Gastroenterology Associates of the Piedmont, PA · Winston-Salem, United States
  • University of Cincinnati · Cincinnati, United States
  • Southern Star Research Institute, LLC · San Antonio, United States
across 3 updates, Oct 15, 2026 – Nov 9, 2026
Start date
Aug 6, 2026→Sep 25, 2026
Oct 15, 2026
Contact
Study contact's phone or email changed: •••5290→none listed. See the current contact
Nov 13, 2026
Show all 4 updates
  1. Nov 13, 2026
    Contact Study contact's phone or email changed: •••5290→none listed. See the current contact
  2. Nov 9, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Endevour Health · Skokie, United StatesNot yet recruiting→Recruiting
    • Newton-Wellesley Hospital · Newton, United StatesNot yet recruiting→Recruiting
    • University of Massachusetts Memorial Healthcare · Worcester, United StatesNot yet recruiting→Recruiting
    • Henry Ford Hospital · Detroit, United StatesNot yet recruiting→Recruiting
  3. Oct 16, 2026
    Southern Star Research Institute, LLC is now Recruiting
  4. Oct 15, 2026
    4 sites added. 7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • Gastroenterolgy Center of Conneticut · Hamden, United StatesNot yet recruiting→Recruiting
    • Florida International Medical Research · Coral Gables, United StatesNot yet recruiting→Recruiting
    • San Marcus Research Clinc, Inc · Miami Lakes, United StatesNot yet recruiting→Recruiting
    • Belis Delgado, MD PA · Miami Springs, United StatesNot yet recruiting→Recruiting
    • Infectious Disease Consultants of Georgia · Athens, United StatesNot yet recruiting→Recruiting
    • DiGiovanna Institute for Medical Education and Research · Massapequa, United StatesNot yet recruiting→Recruiting
    • Romano, Pontzer & Associated · Pittsburgh, United StatesNot yet recruiting→Recruiting
    Show 4 added (4 United States)
    • University of Minnesota · Minneapolis, United States
    • Gastroenterology Associates of the Piedmont, PA · Winston-Salem, United States
    • University of Cincinnati · Cincinnati, United States
    • Southern Star Research Institute, LLC · San Antonio, United States
    Start date Aug 6, 2026→Sep 25, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07513285
Lead sponsor
Acurx Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Sep 25, 2026
Primary completion
Sep 29, 2027 (estimated)
Completion
Nov 24, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Dee Rodriguez
Contact
dee.rodriguez@acurxpharma.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion